^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T

    i
    Other names: CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T
    Associations

    News

    Trials
    Company:
    SZGIMI
    Drug class:
    CD123-targeted CAR-T immunotherapy, CD33-targeted CAR-T immunotherapy, CD38-targeted CAR-T immunotherapy, CLL-1-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    Universal CAR-T Cells Targeting AML (clinicaltrials.gov)
    P1, N=30, Recruiting, Shenzhen Geno-Immune Medical Institute
    New P1 trial • CAR T-Cell Therapy
    |
    CD38 (CD38 Molecule) • CD33 (CD33 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 expression
    |
    CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T